On the morning of the 8th, ABL Bio entered a short-term correction phase, showing a decline of more than 10%. Although expectations for antibody-drug conjugate (ADC) and bispecific antibody platform technologies continue, the stock price is taking a breather due to the combination of overall weakness in the domestic stock market and a correction in the biotech sector.

As of that morning, ABL Bio was trading at 89,700 won, down 10,100 won (10.12%) from the previous trading day. Selling pressure continued from the early hours of the session, pushing the stock down to the 89,500 won level and expanding volatility. Looking at the recent stock price trend, ABL Bio had risen to 119,600 won at the end of May before entering a correction phase. Since then, overlapping profit-taking sell-offs and market volatility have led to a gradual decline in the stock price.

[Core Pipeline and Future Outlook] The market is closely watching the development status of ABL Bio's core pipeline. The company is developing anti-cancer drugs based on its bispecific antibody platform and is evaluated as one of the leading domestic biotech companies through its technology transfer achievements with global pharmaceutical firms.

In particular, the potential for integrating its technology into the ADC field has recently garnered market attention. ADCs are next-generation anti-cancer treatments that selectively deliver drugs to cancer cells using antibodies, and they are considered a major investment area in the global pharmaceutical industry. It is known that ABL Bio recently participated in a global ADC-related event to introduce its technological competitiveness. The market views future R&D achievements and the expansion of global partnerships as key points to watch.

[Investment Considerations and Industry Evaluation] However, investors should note that due to the nature of the biotech sector, stock price volatility may expand depending on R&D schedules and clinical results. Recently, expanded volatility in the U.S. stock market and interest rate uncertainty have also acted as a burden on growth stocks in general. The biotech sector is classified as sensitive to changes in the interest rate environment, as expectations for future growth are often reflected in stock prices.

The industry evaluates that ABL Bio's bispecific antibody platform technology and global technology transfer experience can serve as mid-to-long-term competitive advantages.

[This article was written based on public market data and provided market price information, and utilized artificial intelligence (AI) technology in the process of drafting the article and organizing information. The final content was prepared through a review and editing process. The information provided in this article is intended for general investment information purposes and is not a recommendation to invest in specific stocks or financial products. Investing in the stock and financial markets carries the risk of principal loss, and all responsibility for investments lies with the investor. Please be sure to check related disclosures and official materials before making investment decisions. This publication does not bear legal or financial responsibility for the information.]